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tyramine-modified gellan gum hydrogels in a
cartilage-on-a-chip model
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F. R. Maia, ab H. Pereira,abcd D. Caballero, ab S. C. Kundu,ab R. L. Reisab and
J. M. Oliveira *ab
Rheumatoid arthritis (RA) is an autoimmune and chronic inflammatory disease characterized by joint
inflammation. Since the inflammatory condition plays an important role in the disease process, it is
important to develop and test new therapeutic approaches that specifically target and treat joint
inflammation. In this study, a human 3D inflammatory cartilage-on-a-chip model was established to test
the therapeutic efficacy of anti-TNFa mAb-CS/PAMAM dendrimer NPs loaded-Tyramine-Gellan Gum in
the treatment of inflammation. The results showed that the proposed therapeutic approach applied
to the human monocyte cell line (THP-1) and human chondrogenic primary cells (hCH) cell-based
inflammation system revealed an anti-inflammatory capacity that increased over 14 days. It was also
possible to observe that Coll type II was highly expressed by inflamed hCH upon the culture with anti-
TNF a mAb-CS/PAMAM dendrimer NPs, indicating that the hCH cells were able maintain their biological
function. The developed preclinical model allowed us to provide more robust data on the potential
therapeutic effect of anti-TNF a mAb-CS/PAMAM dendrimer NPs loaded-Ty-GG hydrogel in a
physiologically relevant model.
Introduction
Rheumatoid arthritis (RA) is an autoimmune and chronic
inflammatory disease characterized by joint inflammation.
In the inflammatory scenario, inflammatory cytokines such as
Tumor necrosis factor (TNFa) lead to macrophages activation,
which can cause stiffness and swelling of joints, damage to
cartilage and erosion of bone.1–3 Several therapies are currently
available for RA treatment, including glucocorticoids, disease-
modifying antirheumatic drugs, non-steroidal anti-inflammatory
drugs, and biological agents to relieve pain and control
inflammation.4,5 Despite the great advances, due to heterogeneity
of RA, many patients do not reach continued clinical remission or
become resistant to drug therapy.6,7
In vivo animal models are considered the gold standard in
preclinical studies of pathophysiological mechanisms of RA.8,9
Although animal models present many aspects of human
arthritic diseases and are highly useful for testing new
therapeutic approaches, they show some limitations, such as
the development of arthritis only in predisposed strains of
rodents.10,11 They present limited development of arthritis, and
pathophysiology in animals does not fully mimic the human
pathogenic disease.12,13 Furthermore, an increased amount of
evidence suggest that current animal models are inadequate for
wide drug screening due to their low reproducibility in clinical
trials due to interspecies variations.14,15 Thus, better models are
crucial to help improve our knowledge on the pathological
mechanisms of RA at pre-clinical level, as well as to develop
and test new therapeutic approaches in order to meet patient
and medical needs.16,17 Having these considerations in mind,
research has evolved into the next-generation in vitro screening
platform based on the development of microphysiologically
relevant systems, such as tissue- and organs-on-chips.18
That models are generally based on primary or patient-derived
cells, and can better mimic the disease and its treatment,
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therefore promoting the translational process to humans, while
decreasing the number of animals experiments.19,20 The purpose
of such type of in vitro technology is to provide an artificial
testing system that fully mimics an tissue, organ, or the human
body.21 The chip platform can allow regulating indirect and
direct cell–cell communication as well as biomechanical signals
using several strategies such as the generation of a gradient
flow.22 The use of microfluidic-based technology thus can
address the handicaps between in vitro and in vivo models
presenting new promising approaches to research in medicine.23,24
In our previous work, monoclonal anti-TNFa antibody
(anti-TNFa mAb) linked to chondroitin sulfate (CS) modified
poly(amidoamine) (CS/PAMAM) dendrimer nanoparticles
(NPs)25 and loaded into Tyramine-Gellan Gum (Ty-GG) hydrogels
were developed as a promising drug delivery vehicle to improve
therapeutic efficacy in the treatment of inflammatory conditions
such as RA. The therapeutic efficacy was evaluated using an
inflammation in vitro model under standard static conditions
and dynamic conditions using a bioreactor. In static and
dynamic conditions, the Ty-GG hydrogel encapsulated with
anti-TNFa mAb-CS/PAMAM dendrimer NPs exhibited good
anti-inflammatory activity over time, motivating us to study the
efficacy of this approach in the treatment of inflammation in a
more physiologically relevant in vitro system, such as a 3D
microfluidic platform. In this context, a new in vitro human 3D
inflammatory cartilage-on-a-chip model was developed aiming
to be used as a drug screening platform. An inflammatory
environment was established by means of culturing human
primary chondrocytes exposed to active pro-inflammatory
macrophages, and the anti-TNFa mAb-CS/PAMAM dendrimer
NPs loaded-Ty-GG hydrogel was used to test its anti-
inflammatory therapeutic efficacy.
Of the best of our knowledge, this is the first cartilage-on-
chip model using the combination of several fields such as
nanotechnology, microfluidics and natural based biomaterials.
This work pretends to evolve into the next-generation of
in vitro screening platforms in order to meet patient and
medical needs.
Material and methods
In vitro studies under a 3D microfluidic platform
To mimic the human cartilage inflammation microenvironment,
a complex 3D microfluidic chip-based in vitro model was
developed. In this sense, human monocyte cell line (THP-1)
and human chondrogenic primary cells (hCH) were used in this
study, by means of encapsulation in Matrigels and further
perfuse in the microfluidic platform.
Chondrogenic cell isolation
The hCH cells (passage = 3) previously isolated and characterized
(kindly provided by Raphael Canadas) were used for these
assays.26 Briefly, they were obtained from human cartilage
during arthroscopic surgeries on male and female donors with
ages between 19 and 56 years (Centro Hospitalar Póvoa do
Varzim). The articular cartilage was removed from the bone
and cut into small pieces. The samples were washed several
times with 1% PBS/antibiotic–antimycotic (v/v) solution,
digested with 0.08% collagenase type II (Sigma-Aldrich, USA)/
DMEM-F12 medium 1 : 1 (v/v) and incubated at 37 1C in a water
bath overnight with gentle agitation. The digested tissue was
filtered, and cell suspension centrifuged at 500 G for 5 minutes.
The isolated cells were then plated in flasks cultured in
DMEM-F12 medium and kept in the CO2 incubator at 37 1C
until they reach the desired confluence.
Cell culture
hCH cells were expanded in DMEM/F12 medium (Dulbecco’s
Modified Eagle Medium: Nutrient Mixture F-12, Alfagene,
Portugal), supplemented with 10% of Heat Inactivated Fetal
Bovine Serum (FBS) (Alfagene, Portugal), sodium bicarbonate
(Sigma-Aldrich, USA) and 1% (v/v) antibiotic–antimycotic
(Alfagene, Portugal), under standard culture conditions (at 37 1C
in a 5% CO2 incubator).
THP-1 cells (SIGMA, USA) were expanded in RPMI 1640
Medium, GlutaMAXt Supplement, HEPES (Thermo Fisher
Scientific, USA), supplemented with 10% of FBS and 1% of
antibiotic–antimycotic, under standard culture conditions
(37 1C in a humidified atmosphere containing 5% CO2).
Production and encapsulation of anti-TNF a mAb-CS/PAMAM
dendrimer NPs into Ty-GG hydrogel
Anti-TNFa mAb-CS/PAMAM dendrimer NPs and Ty-GG were
produced as previously described.27,28 Herein, these systems
were used to obtain anti-TNFa mAb-CS/PAMAM dendrimer NPs
loaded-Ty-GG hydrogel. The hydrogel was prepared by mixing
1% (w/v) of Ty-GG solution with anti-TNFa mAb-CS/PAMAM
dendrimer NPs at a final concentration of 0.5 mg mL1. Then,
the enzymatic crosslinking was made by adding horseradish
peroxidase (HRP) solution (0.84 mg mL1) (Sigma-Aldrich, USA)
and hydrogen peroxide solution (H2O2) (0.36% (v/v)) (VWR,
USA) prepared in PBS and water, respectively. mAb-CS/PAMAM
dendrimer NPs loaded-Ty-GG hydrogel (hereafter designated
NPs-Hydrogel) was used in the subsequent assays.
Seeding on microfluidic chip
To perform cell seeding, the microfluidic platform 3D Cell
Culture Chips DAX-1 (Aim Biotech, Singapore) was used. The
device consists of three compartments: two lateral channels,
where THP-1 (left side) and hCH cells (right side) encapsulated
in Matrigel mimic the cartilage inflammation microenvironment,
and one central channel where the produced NPs-Hydrogel was
injected to treat the inflammatory environment. The appropriate
culture medium was placed in the lateral channels with a volume
differential (90 mL at inlet and 70 mL at the outlet) to allow fluid
diffusion between the channels.
Encapsulation of gelatin in central channel
Gelatin from porcine skin (Sigma-Aldrich, USA) at 2% (w/v) was
dissolved in water at 50 1C and added to the central channel of
the microfluidic device. This polymer was used as sacrificial
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hydrogel, preventing the Matrigels with encapsulated cells to
leak into the central chamber. The device was placed at 4 1C for
20 minutes for gelification.
Validation of the co-culture by fluorescence imaging
Before the seeding in the microfluidic device, THP-1 and hCH
cells were made fluorescent by means of CellTracker CM-Dil
Dye (Alfagene, Portugal) and CellTracker Green CMFDA Dye,
respectively. hCH confluent cells were detached from the cell
culture flasks using trypsin (0.25% (v/v) trypsin–EDTA
solution), centrifuged at 300 G for 5 minutes, and diluted in a
new cell suspension. THP-1 non-adherent cells were also
centrifuged at 300 G for 5 minutes and diluted in 1 mL of
PBS. After this, the THP-1 and hCH cells were used at a density
of 2  106 cells mL1. THP-1 were incubated with CellTracker
CM-Dil Dye (2 mM) (Alfagene, Portugal) and hCH with
CellTracker Green CMFDA Dye (1 mM) (Alfagene, Portugal), for
30 minutes at 37 1C. Cells were then centrifuged, encapsulated in
Matrigels and placed in the lateral channels of the chip. RPMI
medium with 100 nM phorbol 12-myristate-13-acetate (PMA)
(Sigma-Aldrich, USA) was added to the channel with THP-1 cells,
to differentiate them into macrophage phenotype, and
DMEM-F12 was added to the channel with hCH cells. The
microfluidic device was incubated for 72 hours and observed
under fluorescence microscopy (Dil tracker ex/em 553/570 nm
Green tracker ex/em 492/517 nm) in the Fluorescence Inverted
Microscope (Axio Observer, Zeiss). Images were acquired using
the Zen microscope processing software, connected to the digital
camera Axio Observer.
Encapsulation of hCH and THP-1 in lateral channels to
stimulate an inflammatory environment
The hCH and THP-1 cells were centrifuged at 300 G for 5 minutes
and diluted in a new cell suspension with appropriate media.
Then, the THP-1 and hCH cells were encapsulated in Matrigels at
a density of 2  106 cells mL1. THP-1 cells suspended in
Matrigels were injected in the left channel and hCH in the right
channel of the microfluidic device, followed by incubation for
20 minutes at 37 1C for crosslinking. After this, RPMI medium
with 100 nM PMA was added to the channel with THP-1 cells and
DMEM-F12 was added to the channel with hCH cells to prevent
drying. A differential of cell culture medium was added to the
inlet (90 mL) and outlet (70 mL) of the microchannel to allow
perfusion and nutrition of the cells. The microfluidic devices were
incubated for 24 hours, after which the medium was replaced
with RPMI medium without PMA in the THP-1 channel
and DMEM-F12 in hCH channel, followed by another 24 hours
of incubation.
To enable an inflammatory response, THP-1 cells were
incubated for 5 hours with 100 ng mL1 of lipopolysaccharide
(LPS) (SigmaAldrich, USA) in RPMI medium. After incubation
time, gelatin was flushed from the central channel with PBS at
50 1C, letting the channel free to add our formulation of
NPs-Hydrogel, for 3 and 7 days. In parallel, a positive control
chip comprising THP-1 stimulated with LPS in left channel,
and hCH in the right channel without NPs-Hydrogel was used
(hereafter designated CTRL+). Additionally, a negative control
chip with THP-1 differentiated with PMA in the left channel,
and hCH cells in the right channel without NPs-hydrogel was
used (hereafter designated CTRL).
Alamar blue assay
Alamar blue was performed to assess the effect of NPs-Hydrogel
in terms of metabolic activity in THP-1 and hCH cells for 3 and
7 days. For the Alamar blue metabolic activity assay in 3D, cells
encapsulated in Matrigels were retrieved using Corning Cell
Recovery Solution (Laborspirit, Portugal) for 40 minutes at 4 1C.
After complete Matrigels release, cells were collected to an
Eppendorf tube and centrifuged to a pellet (300 G for 5 minutes).
The supernatant was removed and a culture medium containing
10% (v/v) of AlamarBlues (BioRad, Oxford, UK) was added.
The tubes were kept in the dark, at 37 1C in the CO2 incubator
for 4 hours. Afterwards, 100 mL of each condition were
transferred to 96-well plates. The fluorescence was read at an
excitation wavelength of 530/25 nm and at an emission wave-
length of 590/535 nm, using a microplate reader (Synergy HT,
BioTek, Instruments, USA).
DNA quantification
The proliferation of THP-1 and hCH cells in contact with
NPs-Hydrogel for 3 and 7 days were analyzed by means of DNA
quantification. For DNA quantification, cells encapsulated in
Matrigels were retrieved using Corning Cell Recovery Solution
for 40 minutes at 4 1C and the subsequent protocol was
performed as previously described. After centrifugation, the
supernatant was removed, and ultrapure water was added. The
cells’ lysate solution was stored at 80 1C until further analysis.
Quanti-IT PicoGreen dsDNA Assay Kit (Alfagene, Portugal) was
used to quantify dsDNA, according to manufacturers’ instructions.
Then, the plate was incubated in the dark for 10 minutes and the
fluorescence was read using excitation of 480/20 nm and emission
of 528/20 nm, in a microplate reader (SYNERGY HT, BIO-TEK).
DNA concentration was determined using a standard curve in the
range of 2 to 0 mL mL1.
Live/dead staining
Cell viability of THP-1 and hCH cells cultured in the micro-
fluidic chip’s lateral channels was assessed in the presence of
NPs-Hydrogel for 3 and 7 days, using the live/dead assay.
Initially, the NPs-Hydrogel was flushed with PBS at 50 1C in
the central channel to add the solution of Calcein-AM (1 mM;
live cells in green) (Alfagene, Portugal) and ethidium homo-
dimer (EthD-1 6 mM; dead cells in red) (Laborspirit, Portugal).
The chips were incubated for 40 minutes in the dark, at 37 1C in
the CO2 incubator, to reach the cells in the lateral channels.
After this, the central channel was washed with PBS three
times. The chips were observed under fluorescence microscopy
(EthD-1 ex/em 528/617 nm Calcein-AM; ex/em 495/515 nm) in
the Fluorescence Inverted Microscope. Images were acquired
using the Zen microscope processing software, connected to
the digital camera Axio Observer. A Z-stack function was used to
combine images at different depths into one final image.
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Anti-inflammatory activity of anti-TNF a mAb-CS/PAMAM
dendrimer NPs loaded-Ty-GG hydrogel
To assesses the therapeutic efficacy of NPs-Hydrogel, at each
time point (3 and 7 days), the culture medium was collected
and stored at 80 1C until further analysis. Human TNF-alpha
DuoSET ELISA (R&D Systems, USA) kit and DuoSet Ancillary
Reagent Kit 2 (R&D Systems, USA), for the optimum performance
of the ELISA kit were used to evaluate the anti-inflammatory
activity. TNFa standard solutions with concentrations from
1000 to 0 pg mL1 were also assessed in the ELISA plate to
perform the calibration curve. The optical density at 450 nm was
read in a microplate reader (Synergy HT, BIO-TEK, Winooski,
VT, USA).
Immunofluorescence staining
To evaluate the amount of Collagen Type II (Coll type II) present
in hCH primary cells, immunofluorescence staining was
performed. On the 7th day, the NPs-Hydrogel was flushed from
the central channel of the chip with PBS at 50 1C. For cell
fixation, 10% formaldehyde was added and left to incubate for
15 minutes at RT. Then, the channel was washed twice with
PBS. For permeabilization 0.1% Triton X-100 was added and
incubated for 10 minutes at RT. Then, the channel was washed
twice with PBS. For blocking, the PBS was removed and
replaced with blocking buffer (2% BSA in PBS) and left to
incubate for 2 hours at RT. The blocking buffer was removed
from the central channel and mouse anti-human COL II
monoclonal antibody (Laborspirit, Portugal) in PBS solution
(1 : 250) was added and incubated overnight at 4 1C. Then, the
central channel was washed 3 times with PBS and the secondary
antibody Alexa Fluors 594 donkey anti-mouse (1 : 500) (Invitrogen,
USA) with DAPI (1 : 1000) (VWR International, USA), in PBS solution
and was left to incubate 1.5 hours. The samples were immediately
analyzed by confocal microscopy (Leica, SP8, Germany) (Alexa Fluor
594: ex/em 590/617 nm; DAPI: ex/em 358/461 nm).
Statistical analysis
Statistical analysis was performed with GraphPad Prism 8
version, where a Shapiro–Wilk normality test was done to
assess the data normality. Non-parametric Kruskal–Wallis test
was applied to all assays. Statistical significance was obtained
as *p o 0.05. All results are presented as means  standard
deviations, and all assays were performed in triplicate.
Results and discussion
Development of a 3D inflammatory cartilage-on-a-chip model
In this study, an in vitro 3D inflamed cartilage model-on-a-chip
to test the therapeutic efficacy of NPs-Hydrogel was established.
The first steps consisted in the encapsulation of pro-
inflammatory THP-1 cells in Matrigels in one of the lateral
channels of the chip to mimic the intended inflammatory
environment, while hCH cells encapsulated in Matrigels
were seeded on the other microchannel, as target cells.
NPs-Hydrogel was added to be used as a treatment option.
In the sense, anti-TNF a mAb-CS/PAMAM dendrimer NPs are
released from the hydrogel and the biological effect was
evaluated.
In order to achieve this, the traditional ‘‘sandwich’’ micro-
fluidic design was chosen.29 The selected microfluidic has a
central chamber and two perfusable lateral channels. THP-1
cells encapsulated in Matrigels were seeded in the left channel,
hCH were seeded in the right channel, and NPs-Hydrogel was
added in the central channel (Fig. 1a).
To assess the achievement and maintenance of the culture
for 3 days, THP-1 cells encapsulated in Matrigels were labelled
with CellTracker CM-Dil Dye (Blue) and hCH with CellTracker
Green CMFDA Dye (Green), as shown in (Fig. 1b). It was
possible to observe that the cells remained in the lateral
channels and were well distributed along the channel in the
Matrigels after 3 days of culture.
Influence of anti-TNF a mAb-CS/PAMAM dendrimer NPs
loaded-Ty-GG hydrogel on metabolic activity and cell
proliferation of THP-1 and hCH cells
Cell viability was assessed by means of Live/Dead assay for
3 and 7 days. At each time point, live (green) and dead (red)
THP-1 and hCH cells were stained by adding Calcein/EthD and
the chips were observed under fluorescence microscopy (Fig. 2).
As observed in Fig. 2a, at day 3, all the conditions tested showed
that THP-1 cells differentiated with PMA (healthy cells CTRL),
stimulated with LPS (inflamed cells CTRL+) and inflamed
THP-1 cells with NPs-Hydrogel remained viable (all green cells)
and no dead cells (red) were found. So, it was possible to verify
Fig. 1 Design of microfluidic chip. (a) Schematic representation of a 3D
inflamed cartilage model-on-a-chip. (b) Fluorescence microscopy image
of microfluidic lateral channel mimicking inflamed cartilage comprising
THP-1 cells embedded in Matrigels (left channel, stained with blue) and
hCH cells (right channel, stained with green), after 3 days of culture (scale
bar = 100 mm).
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that inflamed THP-1 cells remain viable, as seen in other
studies30,31 and that NPs-Hydrogels have no cytotoxic effects
on cells.
Furthermore, the healthy THP-1 cells did not affect the
viability of hCH with no cell death detected. However, hCH
cells in the presence of inflamed THP-1 cells showed cell death.
The same pattern was seen in inflamed THP-1 with NPs-Hydrogel,
but the incidence of dead chondrocytes appears to be lower.
On the seventh day (Fig. 2b), all the THP-1 conditions maintained
a high incidence of cell viability. In addition, it was possible to
observe a higher chondrocytes adhesion through the observation
of the cytoplasmic membrane and a higher incidence of dead
chondrocytes was verified in the inflamed THP-1 condition.
As expected, the healthy THP-1 cells did not affect the viability
of hCH cells over time. Furthermore, inflamed THP-1 cells
subjected to the presence of NPs-Hydrogel also did not affect
the cell viability. Moreover, in an inflammatory environment, it
allowed to reduce the cell death of chondrocytes, showing the
possible therapeutic efficacy of the approach under study.
However, inflamed THP-1 cells induced hCH cell death. Thus,
these results are in agreement with other studies.32,33 In fact,
inflammatory environment induces chondrocytes cell death, as
seen in patients with RA.32,33
Cells’ metabolic activity and proliferation were determined
by means of performing Alamar blue and DNA quantification
assays, respectively, for 3 and 7 days (Fig. 3). As depicted in
Fig. 3a, at the first time point, THP-1 cells (differentiated THP-1,
inflamed THP-1, and inflamed THP-1 cells with NPs-Hydrogel)
showed high metabolic activity with no significant differences
between conditions. In addition (Fig. 3b), it was possible to verify
that the healthy THP-1 cells did not negatively affect the meta-
bolic activity of chondrocytes. However, inflamed THP-1 cells
negatively and significantly affected the metabolic activity of
chondrocytes as compared to the previous condition, as
expected.32,33 In inflamed THP-1 cells with NPs-Hydrogel,
despite a slight decrease, there was no significant difference in
metabolic activity. On the seventh day of culture, there was a
slight increase in metabolic activity in all conditions with THP-1
cells, with no significant differences between them. As expected,
there was an increase in the metabolic activity in the chondro-
cytes when were in contact with healthy THP-1 cells and
inflamed THP-1 cells with NPs-Hydrogel. Nevertheless, inflamed
THP-1 cells induced a significant decrease in the metabolic
activity of chondrocytes, when compared with healthy THP-1
cells, corroborating previous Live/Dead results (Fig. 2a and b).
DNA quantification was also analyzed to assess THP-1 and
hCH cells’ proliferation in contact in the different conditions
for 3 and 7 days. As depicted in Fig. 3c, none of the conditions
negatively affected the proliferation of THP-1 cells after 3d of
culture. However, it was observed a decrease in the proliferation
of THP-1 cells in all conditions, after 7 days of culture. These
results are in agreement with other studies34,35 wherein PMA
induces differentiation of cells and while cells are spending
energy to differentiate. Furthermore (Fig. 3d), it was possible
to verify that healthy THP-1 cells also did not affect the
chondrocytes metabolic activity, observing an increase in
proliferation over time. The hCH cells in contact with inflamed
THP-1 cells with NPs-Hydrogel maintain a constant profile of
proliferation over time. In addition, inflamed THP-1 cells signifi-
cantly decreased cell proliferation of chondrocytes as compared
to healthy cells over time, corroborating the results obtained
from Alamar blue observations.
Anti-TNF a mAb-CS/PAMAM dendrimer NPs loaded-Ty-GG
hydrogel to modulate the inflammatory environment
In our previous work, NPs-Hydrogel was developed. This system
demonstrated a good anti-inflammatory activity over time,
Fig. 2 Live/dead assay of THP-1 and hCH cells. Healthy CTRL (THP-1
differentiated with PMA cultured with hCH); Inflamed CTRL+ (THP-1
stimulated with LPS cultured with hCH); and NPs-Hydrogel (inflamed
THP-1 cultured with hCH with NPs-Hydrogel treatment) for 3 (a) and
7 days (b).
Fig. 3 Evaluation of metabolic activity and proliferation of THP-1 and hCH
cells. (a) Metabolic activity assessed within the three conditions: Healthy
THP-1 (CTRL) cultured with hCH, Inflamed THP-1 (CTRL+) cultured with
hCH, and Inflamed THP-1 cultured with hCH, and with NPs-Hydrogel
treatment for 3 and 7 days. (b) Cell proliferation assessed by DNA quantification
within the three conditions: Healthy THP-1 (CTRL) cultured with hCH,
Inflamed THP-1 (CTRL+) cultured with hCH, and Inflamed THP-1 cultured with
hCH, and with NPs-Hydrogel treatment for 3 and 7 days. Data shown as
Mean  SD. * denotes statistical significant difference p o 0.05.
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allowing the retention of a high percentage of TNFa present
within the inflammatory environment. For more reliable
testing of the effectiveness of this approach in a more
physiologically-relevant microenvironment, the microfluidic
device was used as a preclinical model for drug screening.
In order to assess the therapeutic efficacy of NPs-Hydrogel in
inflamed THP-1 and hCH cells, the levels of free TNFa in the
medium of 7 days of culture were quantified using ELISA KIT
(Fig. 4). THP-1 cells differentiated with PMA (healthy cells) were
used as the negative control, and THP-1 stimulated with LPS
were used as the positive control (inflamed cells). On day 3, the
results demonstrated that the induction of inflammation was
successful, with a low TNFa amount present in healthy THP-1
cells and high TNFa amount in inflamed THP-1 cells, with
significant differences between the conditions. Furthermore, in
the inflamed THP-1 cells with NPs-Hydrogel condition, there
was a decrease in the free TNFa in the medium when compared
with inflamed cells. However, there was no significant differences
as compared with healthy cells. hCH cells in a healthy THP-1
environment also showed low amounts of TNF a present in the
medium but in contrast, hCH in an inflamed THP-1 environment
demonstrated high levels of free TNFa, with significant
differences between the conditions. This means that the mimicry
of the inflammatory environment in the cartilage was successful.
In the inflamed THP-1 environment with NPs-Hydrogel, a low
amount of TNFa in hCH cells was found in the culture medium
when compared to the inflamed and untreated environment.
On day 7, in the condition with inflamed THP-1 cells and
NPs-Hydrogel, the amount of free TNFa present in the medium
decreased significantly when compared to the inflamed THP-1
condition without treatment. Furthermore, the same behavior was
found in chondrogenic cells with NPs-Hydrogel, where the
amount of free TNFa in the medium decreased substantially
when compared to the inflamed hCH condition. So, these results
show that the inflamed THP-1 cells induced the production of an
inflammatory environment in chondrocytes, indicating that the
production of the inflammatory cartilage model was successfully
achieved. In addition, this preclinical model allowed to reveal the
possible therapeutic effect of NPs-Hydrogel in terms of protecting
the chondrocytes from inflammation, corroborating the results
obtained in other studies.36,37 In fact, anti-tumor necrosis factor
(TNF) therapies have been successfully used in the treatment of
RA.36,37 Importantly, it was shown that even linked to dendrimer
NPs and encapsulated in the hydrogel, they maintain therapeutic
efficacy over time.
Collagen type II as a marker of chondrocyte functionality
Articular cartilage is composed of chondrocytes surrounded by
a specialized matrix constituted predominantly of Coll type II
and proteoglycan.38,39 Rheumatoid Arthritis is a chronic
inflammatory disease characterized by joint inflammation that
induces cartilage destruction.40,41 As Coll type II degradation
may indicate cartilage destruction in the joints of RA patients, it
is an important parameter to evaluate since it can be useful as a
disease-specific biomarker.42,43
In this sense, the immunofluorescence staining was performed
to qualitatively evaluate the presence of Coll type II in the
chondrogenic cells matrix, under the three conditions: healthy
THP-1 cells cultured with hCH, inflamed THP-1 cultured with
hCH, and inflamed THP-1 cultured with hCH, and with NPs-
Hydrogel treatment after 7 days of culture (Fig. 5). The results
demonstrated that the state of THP-1 cells can influence the Coll
type II marker in the hCH, being highly expressed in conditions
where hCH were in contact with healthy THP-1 cells and with
inflamed THP-1 cells with NPs-Hydrogel. However, in an
inflammatory environment without NPs-Hydrogel, the incidence
of Coll type II was very low, being in agreement with what was
previously mentioned: the inflammation process induces Coll
type II degradation.42,43 These results can suggest that the
possible therapeutic efficacy of NPs-Hydrogel in this approach.
Despite the promising results, these assays were performed
in normoxia conditions. However, hypoxia is the predominant
microenvironment characteristic in inflamed cartilage.44,45 The
increased oxygen consumption by inflamed cells and the
infiltration of the immune cells with an interrupted blood
supply caused by vascular dysfunction leads to tissue hypoxia in
RA.46,47 In this sense would be interesting, and will be the focus
of future works, to evaluate this preclinical model in a hypoxic
Fig. 4 Quantification of free TNF a in the culture medium. Amount of free
TNF a within the three conditions: healthy THP-1 (CTRL) cultured with
hCH; Inflamed THP-1 (CTRL+) cultured with hCH; and Inflamed THP-1
cultured with hCH, and with NPs-Hydrogel treatment for 3 and 7 days.
Data shown as Mean  SD. * denotes statistical significant difference
p o 0.05.
Fig. 5 Immunofluorescence staining of Coll type II in the chondrogenic
cells matrix. Coll type II expression was assessed in hCH cultured within the
three conditions: Healthy (CTRL) that corresponds to healthy THP-1 cultured
with hCH, Inflamed (CTRL+) that corresponds to inflamed THP-1 cultured
with hCH, and NPs-Hydrogel that corresponds to inflamed THP-1
cultured with hCH, and with NPs-Hydrogel treatment for 7 days. Coll type
II stained in red; Nucleus stained in blue. Scale bar = 50 mm.
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scenario assess whether it would influence the results, and
to mimic more precisely the cartilage inflammation
environment.
Conclusion
Of the best of our knowledge, and up to this date, this was the
first time a cartilage-on-chip was developed using at the same
time several fields such as nanotechnology, microfluidics and
natural based biomaterials in this combination. The relative
complexity of this co-culture model can represent both the
healthy and the disease scenario in the cartilage during an
inflammation case, such as rheumatoid arthritis, depending
on whether the THP-1 cells are stimulated to produce an
inflammatory environment or not. This was achieved by
stimulation of the pro-inflammatory phenotype of THP-1 to
mimic the intended inflammatory environment and the use of
human chondrogenic cell as the target cells. The NPs-loaded
hydrogels were used as anti-inflammatory treatment.
In this work, the results showed that THP-1 and hCH cells
encapsulation in Matrigels and the establishment of the
inflammatory environment by co-culturing them on-chip
was successful. The THP-1 and hCH cells cultured with
NPs-Hydrogel were metabolic active and proliferative along
the study time. Furthermore, Live/Dead assays corroborated
these results and showed that cell death was lower in hCH
cell-based inflammation system cultured with NPs-Hydrogel
when compared to the inflamed environment without
NPs-hydrogel treatment. In addition, the THP-1 and hCH cell-
based inflammation model cultured with the therapeutic
approach presented an increased anti-inflammatory capacity
over time.
It was also possible to observe that Coll type II is highly
expressed in hCH cell-based inflammation system cultured
with NPs-Hydrogel, while its expression was not observed in a
pro-inflammatory environment, indicating that in addition to
modulating the inflammatory environment, the hCH maintain
biological functionally. These important data supported the
results obtained in the previous works on the effectiveness of
this system regarding inflammation treatment. So, the preclinical
model developed allows us to obtain more robust data on
the potential therapeutic of NPs-Hydrogel in an in vivo-like
inflammation environment, namely, to be used in the
treatment of RA.
Altogether, this work provided valuable information on the
delivery of hydrogel-based drug carriers to better understand
their clinical potentials prior to the resource intensive animal
and clinical studies.
With this manuscript, we have evolved into the next-
generation of in vitro screening platforms, approaches in order
to meet patient and medical needs.
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